Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
European Journal of Clinical Investigation|November 18, 2014
Increased large VLDL particles confer elevated cholesteryl ester transfer in diabetesRobin P F Dullaart, Rindert de Vries, Arjan J Kwakernaak, et al.
Clinical Endocrinology|June 29, 2007
Carotid artery intima media thickness is inversely related to serum free thyroxine in euthyroid subjectsRobin P F Dullaart, Rindert de Vries, Carolien Roozendaal, et al.
Clinical Endocrinology|September 20, 2007
Phospholipid transfer protein activity is determined by type 2 diabetes mellitus and metabolic syndrome, and is positively associated with serum transaminasesRobin P F Dullaart, Rindert de Vries, Geesje M Dallinga-Thie, et al.
Clinical Laboratory|August 27, 2005
Post-heparin plasma lipoprotein lipase, but not hepatic lipase activity, is related to plasma adiponectin in type 2 diabetic patients and healthy subjectsRindert De Vries, Bruce H R Wolffenbuttel, Wim J Sluiter, et al.
Atherosclerosis|April 18, 2013
Low normal thyroid function enhances plasma cholesteryl ester transfer in Type 2 diabetes mellitusMichela Triolo, Arjan J Kwakernaak, Frank G Perton, et al.
European Journal of Endocrinology|January 2, 2008
Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterolRobin P F Dullaart, Albert K Groen, Geesje M Dallinga-Thie, et al.
Clinical Laboratory|January 8, 2013
Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitusRindert de Vries, Bert D Dikkeschei, Wim J Sluiter, et al.
The Journal of Clinical Endocrinology and Metabolism|January 22, 2011
Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profileRobin P F Dullaart, Alexander Constantinides, Frank G Perton, et al.
European Journal of Internal Medicine|August 21, 2012
Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativityAlexander Constantinides, Rindert de Vries, Jeroen J J van Leeuwen, et al.
European Journal of Clinical Investigation|September 30, 2011
Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDLPaul J W H Kappelle, Jan Freark de Boer, Frank G Perton, et al.
Pageof 3